Condition: Ulcerative Colitis (Disorder) · Sponsor: Humanitas Clinical and Research Center
The goal of this observational study is to compare the real-life effectiveness and safety of vedolizumab, ustekinumab and JAK inhibitors in patients with UC who had been exposed to at least one anti-TNF-alpha therapy.
This description comes directly from the study's public registry record.
Alessandro Armuzzi · +39 02 8224 5555 · alessandro.armuzzi@hunimed.eu
Always discuss trial participation with your own doctor first.
| Humanitas Research Hospital IRCSS | Mialn, Italy, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06691061